IRINOTECAN CSC infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

irinotecan csc infusioonilahuse kontsentraat

gp-pharm s.a. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 15ml 1tk; 20mg 1ml 5ml 1tk; 20mg 1ml 2ml 1tk; 20mg 1ml 25ml 1tk

OCTREOTIDE CSC süstelahus Eesti - eesti - Ravimiamet

octreotide csc süstelahus

gp-pharm s.a. - oktreotiid - süstelahus - 100mcg 1ml 1ml 5tk

OCTREOTIDE CSC süstelahus Eesti - eesti - Ravimiamet

octreotide csc süstelahus

gp-pharm s.a. - oktreotiid - süstelahus - 50mcg 1ml 1ml 5tk

OCTREOTIDE CSC süstelahus Eesti - eesti - Ravimiamet

octreotide csc süstelahus

gp-pharm s.a. - oktreotiid - süstelahus - 500mcg 1ml 1ml 5tk

GEMCITABINE CSC 1000 MG infusioonilahuse pulber Eesti - eesti - Ravimiamet

gemcitabine csc 1000 mg infusioonilahuse pulber

gp-pharm s.a. - gemtsitabiin - infusioonilahuse pulber - 1000mg 1tk

GEMCITABINE CSC 200 MG infusioonilahuse pulber Eesti - eesti - Ravimiamet

gemcitabine csc 200 mg infusioonilahuse pulber

gp-pharm s.a. - gemtsitabiin - infusioonilahuse pulber - 200mg 1tk

OXALIPLATIN CSC infusioonilahuse pulber Eesti - eesti - Ravimiamet

oxaliplatin csc infusioonilahuse pulber

gp-pharm s.a. - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 50mg 1tk; 5mg 1ml 100mg 1tk

Libtayo Euroopa Liit - eesti - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Adcirca (previously Tadalafil Lilly) Euroopa Liit - eesti - EMA (European Medicines Agency)

adcirca (previously tadalafil lilly)

eli lilly nederland b.v. - tadalafiil - hüpertensioon, kopsuvähk - uroloogilised ravimid - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. efektiivsust on näidatud idiopaatiliste pah-de (ipah) ja kollageen-vaskulaarhaigusega seotud pah-de puhul. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

Cialis Euroopa Liit - eesti - EMA (European Medicines Agency)

cialis

eli lilly nederland b.v. - tadalafiil - erektiilne düsfunktsioon - uroloogilised ravimid - erektsioonihäire ravi. tadalafiili tõhususe tagamiseks on vajalik seksuaalne stimulatsioon. cialis ei ole näidustatud kasutamiseks naistel.